Rationale for Neoadjuvant Chemotherapy for Advanced Gastric Cancer
The recent clinical outcome of treatment for early-stage gastric cancer is excellent in Japan; the 5 year survival rate is more than 90% in patients with stage I disease and 70% in patients with stage II disease. The prognosis of patients with advanced disease (e.g., stage III or IV) remains poor even after complete surgical resection. With such advanced disease, the survival benefit from conventional strategies such as extended surgery with or without postoperative chemotherapy is likely to be limited in consideration of the disappointing results obtained with postoperative adjuvant chemotherapy. A meta-analysis performed by Hermans et al., which analyzed 14 prospective randomized adjuvant trials including 2096 patients, has failed to reveal a consistent beneficiai effect .The analysis was later repeated and published in a letter to the editor in response to suggestions that additional trials should be included . The final odds ratio decreased from 0.88 to 0.67, indicating a possible survival benefit from adjuvant chemotherapy. Although encouraging, it is clear that more definitive trials are necessary to test the efficacy of postoperative adjuvant chemotherapy for high-risk patients.
KeywordsGastric Cancer Advanced Gastric Cancer Preoperative Chemotherapy Unresectable Disease Peritoneal Recurrence
Unable to display preview. Download preview PDF.
- 2.Hermans J, Bonenkamp JJ (1994) Meta-analysis of adjuvant therapy in gastric cancer: in reply. J Clin Oncol 12: 879–880Google Scholar
- 10.Leichman L, Silberman H, Leichman CG, Spears CP, Ray M, Muggia FM, Kiyabu M, Radin R, Laine L, Stain S, et al (1992) Preoperative systemic chemotherapy followed by adjuvant postoperative intraperitoneal therapy for gastric cancer: a University of Southern California pilot program. J Clin Oncol 10:1933–1942PubMedGoogle Scholar
- 11.Kelsen D, Brennan M, Quan V, Saltz L, Huang Y, Klimstra D, Lauers G, Botet J, Lightdale C, Gerdes H, Schwartz G, Karpeh M (1996) Neoadjuvant therapy of high-risk gastric cancer: a phase II trial of preoperative FAMTX and postoperative intraperitoneal fluorouracilcisplatin plus intravenous fluorouracil. J Clin Oncol 14:1818–1828PubMedGoogle Scholar
- 14.Wilke H, Preusser P, Fink U, Gunzer U, Meyer HJ, Meyer J, Siewert JR, Achterrath W, Lenaz L, Knipp H, et al (1989) Preoperative chemotherapy in locally advanced and nonresectable gastric cancer: a phase II study with etoposide, doxorubicin, and cisplatin. J Clin Oncol 7:1318–1326PubMedGoogle Scholar
- 16.Rougier P, Mahjoubi M, Lasser P, Ducreux M, Oliveira J, YChou M, Pignon JP, Elias D, Bellefqih S, Bognel C, et al (1994) Neoadjuvant chemotherapy in locally advanced gastric carcinoma-a phase II trial with combined continuous intravenous 5-fluorouracil and bolus cisplatinum. Eur J Cancer 30A:1269–1275CrossRefGoogle Scholar